ClinicalTrials.Veeva

Menu

STereotactic Ablative Radiosurgery of Recurrent Ventricular Tachycardia in Structural Heart Disease

U

University Hospital Ostrava

Status

Completed

Conditions

Ventricular Tachycardia

Treatments

Procedure: Repeated catheter ablation
Procedure: Radiosurgery

Study type

Interventional

Funder types

Other

Identifiers

NCT04612140
STAR-VT 2020

Details and patient eligibility

About

A multicentre trial on clinical effects of radiosurgical ablation of ventricular tachycardia (VT).

Full description

Patients with previously failed conventional RF catheter ablation will be randomized to radiosurgery (active treatment group) or repeated catheter ablation (control treatment group). Details on inclusion and exclusion criteria are provided below.

Randomization Eligible patients will be assigned to 2 treatment arms - radiosurgery (active arm) or repeated catheter ablation (control arm) in 1:1 fashion by covariate-adaptive randomization algorithm considering age, gender, etiology of structural heart disease (SHD), left ventricular (LV) ejection fraction, and serum B-type natriuretic peptide (NT-proBNP) level.

Enrollment

22 patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients with structural heart disease (SHD) of any etiology (ischemic, non-ischemic, congenital corrected or uncorrected)

  2. Implanted implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy-defibrillator (CRT-D)

  3. Prior ≥1 catheter ablation procedure for VT due to SHD of them the last one performed in the expert center and employed:

    3.1 all meaningful mapping/ablation approaches (endocardial/epicardial access to left / right ventricular substrate as possible or appropriate) 3.2 precise electroanatomical mapping of the arrhythmogenic substrate in anticipation of future radiosurgery 3.3 additional mapping of structures used for precise image integration (aortic arch, left main ostium, right ventricular endocardial surface)

  4. VT recurrence after the last catheter ablation fulfilling all criteria as follows:

    4.1 clinically relevant and requiring further intervention 4.2 compatible with the previously characterized arrhythmogenic substrate 4.3 occurred on stable antiarrhythmic medication (mostly amiodarone) unless contraindicated 4.4 reversible cause excluded

  5. Signed an Institutional Review Board (IRB)-approved written informed consent

Exclusion criteria

  1. Age < 20 years
  2. Acute coronary syndrome or recent percutaneous coronary intervention or cardiac surgery (< 3 months)
  3. Primary electrical disease (channelopathy)
  4. Pregnancy or breastfeeding
  5. Chronic heart failure with New York Heart Association (NYHA) Class IV
  6. Serious comorbidities with presumed life expectancy less than one year
  7. Significant peripheral artery disease precluding retrograde aortic mapping

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

22 participants in 2 patient groups

Radiosurgery
Experimental group
Description:
Eligible patients will be assigned to 2 treatment arms - radiosurgery (active arm) or repeated catheter ablation (control arm) in 1:1 fashion by covariate-adaptive randomization algorithm considering age, gender, etiology of SHD, LV ejection fraction, and serum NT-proBNP level.
Treatment:
Procedure: Radiosurgery
Repeated catheter ablation
Active Comparator group
Description:
Eligible patients will be assigned to 2 treatment arms - radiosurgery (active arm) or repeated catheter ablation (control arm) in 1:1 fashion by covariate-adaptive randomization algorithm considering age, gender, etiology of SHD, LV ejection fraction, and serum NT-proBNP level.
Treatment:
Procedure: Repeated catheter ablation

Trial contacts and locations

2

Loading...

Central trial contact

Jiří Hynčica; Petr Vávra, Ass.Prof.,MD,PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems